

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	22 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	2 December 2024
No. of securities held prior to change	<p>Vincent Peter Ippolito – direct</p> <ul style="list-style-type: none"> 10,801,644 Fully Paid Ordinary Shares 12,000,000 Unlisted Options exercisable at \$0.251 expiring 18 July 2023 2,000,000 Performance Rights Rights (expiring 30 November 2026) <p>Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust</p> <ul style="list-style-type: none"> 3,000,000 Unlisted Options exercisable at \$0.115 expiring 23 May 2023
Class	Performance Rights
Number acquired	24,000,000 Performance Rights
Number disposed	Nil

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – issued in accordance with the terms and conditions of the Company’s Employee Awards Plan.
No. of securities held after the change	Vincent Peter Ippolito – direct * <ul style="list-style-type: none"> 10,801,644 Fully Paid Ordinary Shares 24,000,000 Performance Rights (expiring 2 December 2029) <p><i>* 3,000,000 Unlisted Options exercisable at \$0.115 held by Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> expired on 23 May 2023. 12,000,000 Unlisted Options exercisable at \$0.251 held by Mr Ippolito expired on 18 July 2023. 2,000,000 Performance Rights (expiring 30 November 2026) held by Mr Ippolito lapsed since the date of the last notice.</i></p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights as approved by shareholders at the Annual General Meeting held on 4 November 2024.

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Matthew Callahan
Date of last notice	22 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Shenasaby Investments Pty Ltd <Shenasaby A/C> - Mr Callahan is Director of the trustee and a beneficiary of the trust.
Date of change	2 December 2024
No. of securities held prior to change	Shenasaby Investments Pty Ltd <Shenasaby A/C> - Mr Callahan is Director of the trustee and a beneficiary of the trust <ul style="list-style-type: none"> 74,586,791 Fully Paid Ordinary Shares 1,166,667 Performance Rights
Class	Performance Rights
Number acquired	3,000,000 Performance Rights
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issued in accordance with the terms and conditions of the Company's Employee Awards Plan.

No. of securities held after change	Shenasaby Investments Pty Ltd <Shenasaby A/C> - Mr Callahan is Director of the trustee and a beneficiary of the trust <ul style="list-style-type: none"> 74,586,791 Fully Paid Ordinary Shares 3,000,000 Performance Rights (expiring 2 December 2029) * <p><i>* 1,166,667 Performance Rights (expiring 30 November 2026) lapsed since the date of the last notice.</i></p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights as approved by shareholders at the Annual General Meeting held on 4 November 2024.

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Daniel Sharp
Date of last notice	20 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd
Date of change	2 December 2024
No. of securities held prior to change	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd <ul style="list-style-type: none">• 2,131,313 Fully Paid Ordinary Shares• 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025• 666,667 Performance Rights (expiring 30 November 2026)
Class	Performance Rights
Number acquired	3,000,000 Performance Rights
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issued in accordance with the terms and conditions of the Company's Employee Awards Plan.
No. of securities held after change	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd <ul style="list-style-type: none"> • 2,131,313 Fully Paid Ordinary Shares • 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 • 333,333 Performance Rights (expiring 30 November 2026) * • 3,000,000 Performance Rights (expiring 2 December 2029) <p><i>* 333,334 Performance Rights (expiring 30 November 2026) lapsed since the date of the last notice.</i></p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights as approved by shareholders at the Annual General Meeting held on 4 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	18 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	2 December 2024
No. of securities held prior to change	<ul style="list-style-type: none"> 18,836,702 Fully Paid Ordinary Shares 500,000 Performance Rights (expiring 30 November 2026)
Class	Performance Rights
Number acquired	3,000,000 Performance Rights
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issued in accordance with the terms and conditions of the Company's Employee Awards Plan.
No. of securities held after change	<ul style="list-style-type: none"> 18,836,702 Fully Paid Ordinary Shares 3,000,000 Performance Rights (expiring 2 December 2029) * <p>* 500,000 Performance Rights (expiring 30 November 2026) lapsed since the date of the last notice.</p>

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights as approved by shareholders at the Annual General Meeting held on 4 November 2024.
---	--

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	20 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (Including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust.
Date of change	2 December 2024
No. of securities held prior to change	Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust. <ul style="list-style-type: none">• 654,884 Fully Paid Ordinary Shares• 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025• 666,667 Performance Rights Mal Washer Nominees Pty Ltd - Dr Washer is a Director. <ul style="list-style-type: none">• 1,515,151 Fully Paid Ordinary Shares
Class	Performance Rights

+ See chapter 19 for defined terms.

Number acquired	3,000,000 Performance Rights
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issued in accordance with the terms and conditions of the Company's Employee Awards Plan.
No. of securities held after change	<p>Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust.</p> <ul style="list-style-type: none"> • 654,884 Fully Paid Ordinary Shares • 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 • 333,333 Performance Rights (expiring 30 November 2026) * • 3,000,000 Performance Rights (expiring 2 December 2029) <p>Mal Washer Nominees Pty Ltd - Dr Washer is a Director.</p> <ul style="list-style-type: none"> • 1,515,151 Fully Paid Ordinary Shares <p><i>* 333,334 Performance Rights lapsed since the date of the last notice.</i></p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights as approved by shareholders at the Annual General Meeting held on 4 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.